Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisals guidance for untreated multiple myeloma:
- Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable (2025) NICE technology appraisal guidance 1098
- Daratumumab with lenalidomide and dexamethasone for untreated multiple myleloma when a stem cell transplant is unsuitable (2023) NICE technology appraisal guidance 917
- Lenalidomide plus dexamethasone for previously untreated multiple myeloma (2019) NICE technology appraisal guidance 587
- Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (2011) NICE technology appraisal guidance 228
This page was last updated: